- This topic has 29 replies, 9 voices, and was last updated 14 years, 3 months ago by
.
-
When it rains, it pours!!!! Melanoma patients over the last twenty years have not seen any progress in the fight to cure Melanoma. That has all changed in 2011 when the FDA approved Yervoy (Ipi..Ipilimumab), an anti-CTLA-4 monoclonal antibody and Zelboraf (vemurafenib). Well, this all going to change Melanoma from a cancer to a chronic disease that may be stabilized or even cured. The new Kid on the block( PD-1) is another Surface molecule that is unregulated when the T-cells are activated.
When it rains, it pours!!!! Melanoma patients over the last twenty years have not seen any progress in the fight to cure Melanoma. That has all changed in 2011 when the FDA approved Yervoy (Ipi..Ipilimumab), an anti-CTLA-4 monoclonal antibody and Zelboraf (vemurafenib). Well, this all going to change Melanoma from a cancer to a chronic disease that may be stabilized or even cured. The new Kid on the block( PD-1) is another Surface molecule that is unregulated when the T-cells are activated. This molecule is time dependent , which means that over time it migrates to the surface. Base on the research today, PD-1 molecule causes global inhibition to activated T-cells and down regulates the IL-2 expression by the PI3K/Akt pathway. It also inhibits the ICOS molecule that is an important co-stimulator for the T-cells.
So with stakes high to be the first to market, Bristol Myer Squibb, a little known company, Amplimmune, co-sponsored by GlaxoSmithKline and Curetech, a subsidiary of Teva Pharma of Israel are in the race of their lives. Winner takes all. And to throw Icing on the cake, the blockage of both inhibitors (PD-1 and CTLA-4) have shown remarkable ability to eradicate Melanoma tumors in mice.
Bristol Myer Squibb seems to be leading this race with a clinical trials recruiting at Sloan Kettering in New York and Yale in Connecticut.
The study is “Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma”
Trial: NCT01024231So with this in mind, if was seeking to try a clinical trial at time, I would seek out the combination first, then PD-1 and if all else fails, Anti-CTLA-4 therapy followed by IL-2.
I see a Stabilization/Cure on the horizon for this disease and others based on these immunotherapies.
“It is not the strongest of the species that survives, nor the most intelligent, but the one most responsive to change.”
~Charles Darwin~Take Care,
Jimmy B
-
-
-
-
-
-
I would follow your Oncologist's recommendation.
To do the Braf + MEK therapy your tumor must be BRAF positive.
If you have high tumor burden and are BRAF +, I would ask your Onc. about the BRAF + MEK therapy.
If you have High tumor burden and BRAF-, I would seek out the combo Anti-PD-1 + Yervoy at Yale or Sloan Kettering.
If you have Low tumor burden and BRAF-, I would seek out Anti-PD-1 or Yervoy or HD IL-2.
Remember that this is a game of Chess, you want to have a plan action with Alternatives.
"The game is to win"
I hope this helps.
best regards,
Jimmy B
-
I would follow your Oncologist's recommendation.
To do the Braf + MEK therapy your tumor must be BRAF positive.
If you have high tumor burden and are BRAF +, I would ask your Onc. about the BRAF + MEK therapy.
If you have High tumor burden and BRAF-, I would seek out the combo Anti-PD-1 + Yervoy at Yale or Sloan Kettering.
If you have Low tumor burden and BRAF-, I would seek out Anti-PD-1 or Yervoy or HD IL-2.
Remember that this is a game of Chess, you want to have a plan action with Alternatives.
"The game is to win"
I hope this helps.
best regards,
Jimmy B
-
-
-
-
-
-
-
-
-
- You must be logged in to reply to this topic.